RGCC CAMBISEQ™

RGCC CAMBISEQ™

RGCC CAMBISEQ™

What are Identified ?

Predicts efficacy of immunotherapy or targeted therapy.
Identifies beneficial mutations for cancer treatment.

Test Results

4 Weeks *

Test Type

NEXT GENERATION SEQUENCING

Sample Required

Blood sample or FFPE Tissue (Formalin-Fixed Paraffin-Embedded)

Cancer Type

All type of Cancers

Blood Sample Qty

15-20ml peripheral whole blood, Fresh tissue: Minimum 400mg, FFPE: Minimum 100mg (or 1 block)

DESCRIPTION

RGCC cancer analysis, mutational burden and instability sequencing (CAMBISeq) provides next- generation sequencing analysis on both DNA and RNA. RGCC CAMBISeq can help to identify variants in more than 500 genes, help detect fusions, and calculate tumour mutational burden (TMB) and microsatellite instability (MSI). TMB refers to the number of mutations within the coding region and is used as a biomarker of sensitivity to immunotherapy. Highly mutated tumours usually obtain neoantigens which make them targets of activated immune cells. TMB can be accurately measured in a specific panel of genes, helping to avoid the expensive and time-consuming technique of whole exome sequencing.